Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6945204 | 1.00 | L3MBTL1 (0.42) | L3MBTL1CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL13334224 | 0.82 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL8290429 | 0.82 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL18610076 | 0.81 | CHRNB2 (0.37) | L3MBTL1CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL2980585 | 0.81 | CHRNB2 (0.37) | L3MBTL1CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL2980588 | 0.81 | CHRNB2 (0.37) | L3MBTL1CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL23610412 | 0.81 | CYP2D6 (0.47) | — | |
| SCHEMBL2036602 | 0.81 | CYP2D6 (0.47) | — | |
| SCHEMBL3824571 | 0.81 | CYP2D6 (0.47) | — | |
| SCHEMBL7347617 | 0.81 | CYP2D6 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271944-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA | GENENTECH, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-1155013-B1 | HETEROCYCLIC BENZENESULPHONAMIDE COMPOUNDS AS BRADYKININE ANTAGONISTS | FOURNIER IND & SANTE (FR) | 2003-07-23 | — | — | EP | disclosed |
| US-6479515-B1 | FOR THE TREATMENT OF PAIN AND INFLAMMATION, AND ESPECIALLY IN THE TREATMENT OF ASTHMA, CEREBRAL TRAUMATIC SHOCK AND ALLERGIC RHINITIS | FOURNIER INDUSTRIE ET SANTE (FR) | 2002-11-12 | — | — | US | disclosed |
| EP-1155013-A1 | HETEROCYCLIC BENZENESULPHONAMIDE COMPOUNDS AS BRADYKININE ANTAGONISTS | FOURNIER INDUSTRIE ET SANTE (FR) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050418-A1 | HETEROCYCLIC BENZENESULPHONAMIDE COMPOUNDS AS BRADYKININE ANTAGONISTS | FOURNIER INDUSTRIE ET SANTE (FR) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271944-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA | VHL, HIF1AN, FANCI | L3MBTL1 870/4885CHRNB2 4866/4885CHRNA4 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.